TD Cowen Increases Palvella Therapeutics (NASDAQ:PVLA) Price Target to $133.00

Palvella Therapeutics (NASDAQ:PVLA) had its price objective raised by research analysts at TD Cowen from $97.00 to $133.00 in a report issued on Tuesday,Benzinga reports. The firm currently has a “buy” rating on the stock. TD Cowen’s price target suggests a potential upside of 49.47% from the company’s previous close.

PVLA has been the subject of several other research reports. Truist Financial set a $190.00 price target on shares of Palvella Therapeutics in a research report on Monday. BTIG Research upped their price objective on Palvella Therapeutics to $192.00 and gave the stock a “buy” rating in a report on Monday. Raymond James Financial reaffirmed a “strong-buy” rating on shares of Palvella Therapeutics in a research report on Tuesday. Cantor Fitzgerald boosted their price target on Palvella Therapeutics from $120.00 to $200.00 and gave the company an “overweight” rating in a research report on Thursday, November 6th. Finally, HC Wainwright set a $200.00 price target on Palvella Therapeutics in a research note on Monday. Two research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Palvella Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $152.27.

Palvella Therapeutics Trading Down 9.7%

NASDAQ PVLA opened at $88.98 on Tuesday. The business’s 50-day moving average price is $83.82 and its 200 day moving average price is $55.62. Palvella Therapeutics has a twelve month low of $11.17 and a twelve month high of $112.00. The company has a market capitalization of $1.05 billion, a PE ratio of -33.83 and a beta of -0.20.

Palvella Therapeutics (NASDAQ:PVLA) last posted its quarterly earnings data on Monday, November 10th. The company reported ($1.03) EPS for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.18). Equities analysts predict that Palvella Therapeutics will post -3.69 EPS for the current year.

Insider Activity

In other Palvella Therapeutics news, COO Kathleen Goin sold 4,302 shares of the stock in a transaction that occurred on Wednesday, November 19th. The shares were sold at an average price of $86.23, for a total value of $370,961.46. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 20.50% of the company’s stock.

Hedge Funds Weigh In On Palvella Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in PVLA. Archer Investment Corp acquired a new stake in shares of Palvella Therapeutics during the third quarter worth approximately $28,000. Russell Investments Group Ltd. bought a new position in Palvella Therapeutics during the 3rd quarter valued at $36,000. Police & Firemen s Retirement System of New Jersey bought a new position in Palvella Therapeutics during the 2nd quarter valued at $37,000. JPMorgan Chase & Co. grew its holdings in Palvella Therapeutics by 108,066.7% during the 2nd quarter. JPMorgan Chase & Co. now owns 3,245 shares of the company’s stock worth $73,000 after acquiring an additional 3,242 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in shares of Palvella Therapeutics in the 2nd quarter worth about $85,000. 40.11% of the stock is currently owned by hedge funds and other institutional investors.

About Palvella Therapeutics

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc, formerly known as Pieris Pharmaceuticals Inc, is based in WAYNE, Pa.